Functional investigation of the RNA helicase MOV10 with respect to its interplay with factors involved in nonsense-mediated mRNA decay
Journal of Biological Chemistry · 2025
DOI: 10.1016/j.jbc.2025.110418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2025. Verfasst von Guangpu Xue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: RNA Helicases, Nonsense Mediated mRNA Decay, Trans-Activators, RNA, Messenger. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Israeli Foundation for Scientific Research and Development, German Research Foundation, Freie Universität Berlin.
Abstract (Originalsprache)
The RNA helicase Moloney leukemia virus 10 (MOV10) is involved in several RNA processing pathways, including RNA silencing, defense against viral RNA and nonsense-mediated mRNA decay (NMD). MOV10 is a member of the Up-frameshift 1 (UPF1)-family of superfamily 1 (SF1) helicases and like its prototype member, unwinds RNA duplexes bearing a 5'-single-stranded overhang. Sequence comparisons of MOV10 and UPF1 revealed significant identity between their RecA domains and considerable divergence between the N-terminal domains preceding the helicase core. Using in vitro biochemical approaches, we show that the N-terminal domain of MOV10 is functionally distinct from the CH domain of UPF1, both in terms of its impact on catalytic activity and the protein-protein interactions it mediates. MOV10 engages the NMD factor UPF2 via its N-terminal regulatory domain but binds a different region than the UPF1-CH domain. We propose that the interactions mediated by the MOV10-N-terminal domain dictate its localization to cytoplasmic RNA condensates such as P-bodies and stress granules. This is distinct from UPF1, whose localization appears to be driven by its interaction with RNA. Taken together, our work presents a mechanistic model for the recruitment and involvement of MOV10 in NMD, where it was proposed to act as an RNA clearance factor for UPF1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany.
- The Mina & Everard Goodman Faculty of Life Sciences & Institute of Nanotechnology, Bar-Ilan University, Ramat Gan, Israel.
- Laboratory of Structural Biochemistry, Institute of Chemistry and Biochemistry Freie Universität Berlin, Berlin, Germany.
- The Mina & Everard Goodman Faculty of Life Sciences & Institute of Nanotechnology, Bar-Ilan University, Ramat Gan, Israel. Electronic address: Yaron.Shav-Tal@biu.ac.il.
- Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany. Electronic address: chakraba@zedat.fu-berlin.de.
Förderung
- German Israeli Foundation for Scientific Research and Development
- German Research Foundation
- Freie Universität Berlin
Zitieren
APA
Xue, G., Faber, G. P., Pommerening, L. S., Mallick, M., Gupta, A., Wahl, M. C., Shav-Tal, Y., & Chakrabarti, S. (2025). Functional investigation of the RNA helicase MOV10 with respect to its interplay with factors involved in nonsense-mediated mRNA decay. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110418
Vancouver
Xue G, Faber GP, Pommerening LS, Mallick M, Gupta A, Wahl MC, et al. Functional investigation of the RNA helicase MOV10 with respect to its interplay with factors involved in nonsense-mediated mRNA decay. Journal of Biological Chemistry. 2025. doi:10.1016/j.jbc.2025.110418
BibTeX
@article{Xue2025,
author = {Xue, Guangpu and Faber, Gabriel P and Pommerening, Lea S and Mallick, Megha and Gupta, Aditi and Wahl, Markus C and Shav-Tal, Yaron and Chakrabarti, Sutapa},
title = {Functional investigation of the RNA helicase MOV10 with respect to its interplay with factors involved in nonsense-mediated mRNA decay},
journal = {Journal of Biological Chemistry},
year = {2025},
doi = {10.1016/j.jbc.2025.110418}
}
EUVIMED